Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 199 participants.
Also called NCT02296190
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 199 participants
- Registry
-
NCT02296190
-
- Other papers using this trial's data
- Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT02296190. Randomized; double masking; primary purpose treatment. Start 2015-03-27 (registry gives no type); primary completion 2016-12 (actual). Results posted on 2020-12-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm
- Acronym
- NODE-1
- Condition
- Paroxysmal Supraventricular Tachycardia (PSVT)
- Intervention (Drug)
- Etripamil
- Intervention (Drug)
- Placebo
- Lead sponsor
- Milestone Pharmaceuticals Inc.
- Collaborator
- Medpace, Inc.
Record details
- Record id
cardio:ct-nct02296190- Content hash
34a01edbabaf77d405d820a3226171679993dc6168d2358556ebcab234ac2264